ArticleScientific reports2025
Lysyl oxidase as a potential biomarker of lung recurrence after hepatectomy in hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tetrathiomolybdate reduces bone cancer pain and tumor-associated osteoclast activation through copper-dependent LOX signaling.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lung recurrence following hepatectomy is a common and clinically significant complication in patients with hepatocellular carcinoma (HCC), often leading to poor prognosis. However, the underlying mechanisms and reliable predictive biomarkers remain poorly defined. We performed cDNA microarray analysis to identify genes associated with lung recurrence after hepatectomy in HCC patients and identified lysyl oxidase (LOX) as a candidate. We further evaluated the association between LOX expression, circulating tumor cell (CTC), and microvessel density (MVD). The predictive value of serum LOX levels was assessed in both training and validation cohorts. LOX expression was significantly elevated in HCC patients who developed lung recurrence post-hepatectomy and was associated with worse prognosis. High intratumoral LOX expression correlated with increased CTC counts and elevated MVD. In vitro, LOX overexpression enhanced HCC cell migration and invasion, while LOX knockdown suppressed these phenotypes. Serum LOX levels demonstrated predictive potential for postoperative lung recurrence in both cohorts. LOX overexpression is closely associated with lung recurrence after hepatectomy in HCC patients. LOX may serve as a potential biomarker, and its serum level could be used to predict postoperative lung recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.